On October 11, AstraZeneca met the primary endpoint of their antibody combination that can be used to treat and prevent COVID-19. They have discovered that receiving an intramuscular injection of AZD7442 within five days of having COVID-19 symptoms can reduce the risk of dying by 50%.

Currently, the AstraZeneca lab is the only lab that has made a vaccine with Phase 3 data that has shown to be preventative against COVID-19. The trial for the vaccine has been conducted in 96 different sites around the world and has seen a significant effect in COVID-19 patients. 

In the study, 13% of the patients were over the age of 65, and 90% were at high risk of receiving COVID-19 due to being immunocompromised. By the end of the primary phase of the study, researchers saw that individuals that had received the vaccine were at a lower risk of dying from COVID-19 once they had contracted it. 

“With continued cases of serious COVID-19 infections across the globe, there is a significant need for new therapies like AZD7442,” said Professor Hugh Montgomery from the ICU at University College of London. “These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic.”

 On October 5, AstraZeneca submitted a request to the FDA for the approval of AZD7442 for emergency use. In the following months, the company hopes to see lives improved by the research done on this vaccine. 

Hannah Walker

Hannah Walker is a health reporter at The Pavlovic Today.